Imunon (IMNN) Change in Account Payables (2010 - 2018)
Imunon's (IMNN) quarterly Change in Account Payables came in at $3710.0 in Q4 2018, down 99.08% YoY from $403445.0 in Q4 2017, and up 100.85% on a QoQ basis from -$435711.0 in Q3 2018.
Imunon (IMNN) Change in Account Payables (2010 - 2018) Analysis & Trends
Imunon (IMNN) has 9 years of Change in Account Payables data on file, last reported at $3710.0 in Q4 2018.
- Quarterly Change in Account Payables fell 99.08% year-over-year to $3710.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$396225.0 (down 173.66% YoY) and the FY2023 annual result came in at -$2.0 million, down 194.37% from the prior year.
- Change in Account Payables advanced to $3710.0 in Q4 2018, from -$435711.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q1 2017 to a low of -$1.1 million in Q2 2015.
- A 5-year average of $54789.6 and a median of $40250.5 in 2016 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 2410.1% in 2017, down 1349.23% in 2017.
- Tracing IMNN's Change in Account Payables over 5 years: stood at -$949802.0 in 2014, then jumped by 134.38% to $326527.0 in 2015, then slumped by 145.01% to -$146965.0 in 2016, then soared by 374.52% to $403445.0 in 2017, then slumped by 99.08% to $3710.0 in 2018.
- The last three Change in Account Payables figures came in at $3710.0 (Q4 2018), -$435711.0 (Q3 2018), and $601721.0 (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 3,710.00 |
| Dec 31, 2018 | 3,710.00 |
| Sep 30, 2018 | -435,711.00 |
| Sep 30, 2018 | -435,711.00 |
| Jun 30, 2018 | 601,721.00 |
| Jun 30, 2018 | 601,721.00 |
| Mar 31, 2018 | -565,945.00 |
| Mar 31, 2018 | -565,945.00 |
| Dec 31, 2017 | 403,445.00 |
| Dec 31, 2017 | 403,445.00 |
| Sep 30, 2017 | -959,300.00 |
| Sep 30, 2017 | -959,300.00 |
| Jun 30, 2017 | -414,431.00 |
| Jun 30, 2017 | -414,431.00 |
| Mar 31, 2017 | 1.51 Mn |
| Mar 31, 2017 | 1.51 Mn |
| Dec 31, 2016 | -146,965.00 |
| Dec 31, 2016 | -146,965.00 |
| Sep 30, 2016 | 76,791.00 |
| Sep 30, 2016 | 76,791.00 |